Patents by Inventor Timothy Kuan-Ta Lu

Timothy Kuan-Ta Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11875876
    Abstract: Disclosed herein are novel 5? UTR sequences that can be used to control gene expression in various contexts. Also disclosed herein are methods of engineering 5? UTR sequences and methods and kits for screening 5? UTR sequences for a property of interest.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 16, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Manolis Kellis, Jicong Cao, Eva Maria Novoa Pardo, Zhizhuo Zhang
  • Publication number: 20230416846
    Abstract: The present invention relates to a digital CRISPR-based method for detecting and quantitating target nucleic acids in a sample comprising: forming a mixture comprising sample nucleic acids; isothermal amplification reaction reagents for amplifying one or more target nucleic acid sequences; partitioning the mixture into a plurality of compartments; incubating the partitioned mixture at a temperature for isothermal amplification and Cas effector cleavage of an amplified DNA strand, detecting a signal from cleavage of the non-target sequence, thereby detecting the one or more target sequences in the sample, and determining the copy number of the target nucleic acid based on a Poisson distribution of the proportion of positive-to-negative compartments. The invention also relates to a method for detecting presence and/or of a disease in a subject, and a kit to quantitate nucleic acids in a sample.
    Type: Application
    Filed: October 28, 2021
    Publication date: December 28, 2023
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, National University of Singapore
    Inventors: Xiaolin Wu, Hanry Yu, Timothy Kuan-ta Lu
  • Patent number: 11850290
    Abstract: Provided herein, in some embodiments, are hydrogel-elastomer and hydrogel-alginate devices, compositions and associated methods to encapsulate living cells.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 26, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Xinyue Liu, Tzu-Chieh Tang, Eléonore Claire Tham, Xuanhe Zhao
  • Publication number: 20230405144
    Abstract: Provided herein are compositions and methods for inducing cell death in a regulated manner, for example in a safety switch system. Inducible cell death can be triggered by ligand binding to a one or more ligand binding domains. Cell death can include induction of apoptosis.
    Type: Application
    Filed: May 18, 2023
    Publication date: December 21, 2023
    Inventors: Rocky CHEUNG, Russell Morrison GORDLEY, Timothy Kuan-Ta LU, Michelle Elizabeth HUNG, Rebecca Tayler COTTMAN
  • Publication number: 20230270789
    Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
    Type: Application
    Filed: July 25, 2022
    Publication date: August 31, 2023
    Inventors: Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang
  • Patent number: 11718860
    Abstract: Synthetic promoters that are differentially modulated between certain diseased cells (e.g., cancer cells) and normal cells (e.g., non-cancer cells) are described. The synthetic promoters may be used to drive expression of gene(s) of interest in a specific cell type or during a specific cellular state. These synthetic promoters are useful, for example, for targeted expression of therapeutic molecules in diseased cells.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 8, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Lior Nissim, Ming-Ru Wu
  • Patent number: 11591604
    Abstract: Provided herein, in some aspects, are tools (e.g., methods, compositions and nucleic acids) for building genetic circuits in Bacteroides and Parabacteroides bacteria, as well as the bacteria containing the genetic circuits.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 28, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Mark K. Mimee, Christopher Voigt, Alex C. Tucker
  • Publication number: 20230011052
    Abstract: Provided herein are compositions and methods for regulating expression of effector molecules using regulatable transcription factors and/or activation inducible promoters.
    Type: Application
    Filed: June 10, 2022
    Publication date: January 12, 2023
    Inventors: Marcela Guzman Ayala, Russell Morrison Gordley, Michelle Elizabeth Hung, Gary Lee, Jack Tzu-Chiao Lin, Timothy Kuan-Ta Lu, Assen Boyanov Roguev
  • Publication number: 20220396762
    Abstract: The disclosure provides compositions and methods for growing programmable enzyme-functionalized and sense-and-response bacterial cellulose living materials with engineered microbial co-cultures.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 15, 2022
    Applicants: Massachusetts Institute of Technology, Imperial College Innovations Limited
    Inventors: Timothy Kuan-Ta Lu, Tzu-Chieh Tang, Wolfgang Ott, Tom Ellis, Charles Gilbert
  • Publication number: 20220378363
    Abstract: Transient molecules in the gastrointestinal (GI) tract, such as nitric oxide and hydrogen sulfide, are important signals and mediators of inflammatory bowel disease (IBD). Because these molecules may be short-lived in the body, they are difficult to detect. To track these reactive molecules in the GI tract, a miniaturized device has been developed that integrates genetically engineered probiotic biosensors with a custom-designed photodetector and readout chip. Leveraging the molecular specificity of living sensors, bacteria were genetically encoded to respond to IBD-associated molecules by luminescing. Low-power electronic readout circuits (e.g., using nanowatt power) integrated into the device convert the light from just 1 ?L of bacterial culture into a wireless signal. Biosensor monitoring was demonstrated in the GI tract of small and large animal models and integration of all components into a sub-1.4 cm3 ingestible form factor capable of supporting wireless communication.
    Type: Application
    Filed: April 26, 2022
    Publication date: December 1, 2022
    Applicants: Massachusetts Institute of Technology, Trustees of Boston University, The Brigham and Women's Hospital, Inc.
    Inventors: Timothy Kuan-Ta Lu, Rabia Tugce Yazicigil Kirby, Carlo Giovanni Traverso, Jenna Ahn, Maria Eugenia Inda, Miguel Jimenez, Qijun Liu, Phillip Nadeau, Christoph Winfried Johannes Steiger, Adam Wentworth
  • Publication number: 20220378822
    Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
    Type: Application
    Filed: August 28, 2020
    Publication date: December 1, 2022
    Inventors: Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang
  • Publication number: 20220378842
    Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
    Type: Application
    Filed: June 23, 2022
    Publication date: December 1, 2022
    Inventors: Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang, Daniel Frimannsson
  • Patent number: 11446332
    Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 20, 2022
    Assignee: SENTI BIOSCIENCES, INC.
    Inventors: Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang
  • Patent number: 11419898
    Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: August 23, 2022
    Assignee: SENTI BIOSCIENCES, INC.
    Inventors: Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang, Daniel Frimannsson
  • Publication number: 20220090040
    Abstract: Described herein are engineered fusion proteins comprising a variant protease (e.g., an HCV NS3 protease) fused to a polypeptide of interest and a cognate protease cleavage site. The cleavability of the cognate protease cleavage site enables the controllability of one or more functions of the polypeptide of interest. Additionally disclosed are methods for generating engineered fusion proteins as well as their therapeutic use.
    Type: Application
    Filed: January 24, 2020
    Publication date: March 24, 2022
    Applicants: Senti Biosciences, Inc., Senti Biosciences, Inc.
    Inventors: Daniel Frimannsson, Philip Janmin Lee, Timothy Kuan-Ta Lu, Russell Morrison Gordley
  • Publication number: 20220033830
    Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
    Type: Application
    Filed: March 1, 2021
    Publication date: February 3, 2022
    Applicants: Trustees of Boston University, Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Robert James Citorik, James Collins, Russell-John Krom
  • Patent number: 11186830
    Abstract: Disclosed here are recombinant bacteriophages with tail fibers encoded by at least two subsets of genomic fragments from different bacteriophage having different host ranges.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: November 30, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Hiroki Ando, Sebastien Lemire
  • Publication number: 20210347823
    Abstract: Described herein are methods of physicochemical-guided peptide design that utilize specific functional determinants to a protein's property of interest. Also described herein are novel synthetic peptide antibiotics that have increased potency and/or decreased toxicity relative to the template peptide from which they were derived, and methods of use thereof in treating microbial infections.
    Type: Application
    Filed: September 19, 2019
    Publication date: November 11, 2021
    Applicants: Massachusetts Institute of Technology, Fundação Universidade Federal do ABC - UFABC (Federal University of ABC Foundation)
    Inventors: Timothy Kuan-Ta Lu, Cesar de la Fuente Nunez, Vani Xavier de Oliveira Junior, Marcelo Der Torossian Torres
  • Publication number: 20210310022
    Abstract: Described herein are methods and compositions that enable rapid generation of high-order combinations of genetic elements comprising a CRISPR guide sequence and a scaffold sequence, and a barcode for rapid identification of the combination of genetic elements encoded within a single cell or a pooled population. Also described herein compositions of inhibitors of epigenetic genes and methods for reducing cell proliferation and/or treating cancer.
    Type: Application
    Filed: June 3, 2021
    Publication date: October 7, 2021
    Applicant: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Alan Siu Lun Wong, Ching Gee Choi
  • Patent number: 11091762
    Abstract: Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: August 17, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Sebastien Lemire, Andrew C. Yang, Kevin M. Yehl